The study investigates the efficacy and tolerability of paliperidone ER in treating aggression, self-injury, and irritability in adolescents and young adults with autism. Given the increasing prevalence of autism spectrum disorders and the limited treatment options available, successful outcomes could position paliperidone ER as a key therapeutic option in this niche market. The collaboration with Ortho-McNeil Janssen Scientific Affairs, LLC suggests potential for further commercialization and distribution. However, competition from other antipsychotics and emerging therapies targeting similar symptoms must be monitored closely.